Monitor for future enrollment milestones and interim data readouts, which could serve as catalysts. Given early stage and no efficacy data, stock movement likely limited unless enrollment accelerates significantly or safety signals emerge.
Price Chart
Executive Summary
Rein Therapeutics provided a clinical update on its Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF), reporting 8 patients enrolled with enrollment accelerating and clinical trial sites expanding globally. No efficacy or safety data were disclosed, and the update is an early-stage progress report with no material financial impact.
Key Facts
- 8 patients enrolled in Phase 2 RENEW trial for LTI-03 in IPF as of April 29, 2026.
- 2 additional patients expected to be enrolled this week.
- Clinical trial sites active in the United States, Australia, and Poland; UK and Germany expected to open.
- Trial aims to enroll ~120 patients, randomized to two dose levels of LTI-03 or placebo.
- Major efficacy endpoint: change from baseline in forced vital capacity (FVC).
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure: LTI-03 may not meet efficacy endpoints.
- Financing risk: company may need additional capital to complete trials.
- Competition: other IPF therapies in development could limit commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283690 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5830 (−34.43%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5830 (−27.67%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5830 (−34.85%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5830 (−38.55%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5830 (+42.84%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5830 (+42.84%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5830 (+43.40%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5830 (−60.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers